Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
Want to see IN:BALAXI full AI Analyst Report?
Total Valuation
Balaxi Pharmaceuticals Limited has a market cap or net worth of ₹1.29B. The enterprise value is ₹696.20M.
Market Cap₹1.29B
Enterprise Value₹696.20M
Share Statistics
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,207,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Balaxi Pharmaceuticals Limited’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 0.42%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)0.42%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee53.53M
Profits Per Employee277.82K
Employee Count51
Asset Turnover0.81
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Balaxi Pharmaceuticals Limited is 93.7. Balaxi Pharmaceuticals Limited’s PEG ratio is -0.64.
PE Ratio93.7
PS Ratio0.31
PB Ratio0.34
Price to Fair Value0.34
Price to FCF-1.89
Price to Operating Cash Flow8.87
PEG Ratio-0.64
Income Statement
In the last 12 months, Balaxi Pharmaceuticals Limited had revenue of 2.73B and earned 14.17M in profits. Earnings per share was 0.26.
Revenue2.73B
Gross Profit1.14B
Operating Income52.93M
Pretax Income52.93M
Net Income14.17M
EBITDA74.45M
Earnings Per Share (EPS)0.26
Cash Flow
In the last 12 months, operating cash flow was 149.66M and capital expenditures -123.88M, giving a free cash flow of 25.78M billion.
Operating Cash Flow149.66M
Free Cash Flow25.78M
Free Cash Flow per Share0.47
Dividends & Yields
Balaxi Pharmaceuticals Limited pays an annual dividend of ₹0.5, resulting in a dividend yield of ―
Dividend Per Share₹0.5
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-52.84%
50-Day Moving Average25.46
200-Day Moving Average30.71
Relative Strength Index (RSI)41.39
Average Volume (3m)75.37K
Important Dates
Balaxi Pharmaceuticals Limited upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 28, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Balaxi Pharmaceuticals Limited as a current ratio of 4.51, with Debt / Equity ratio of 23.15%
Current Ratio4.51
Quick Ratio4.51
Debt to Market Cap0.65
Net Debt to EBITDA5.79
Interest Coverage Ratio1.36
Taxes
In the past 12 months, Balaxi Pharmaceuticals Limited has paid 38.76M in taxes.
Income Tax38.76M
Effective Tax Rate0.73
Enterprise Valuation
Balaxi Pharmaceuticals Limited EV to EBITDA ratio is 17.26, with an EV/FCF ratio of -2.84.
EV to Sales0.47
EV to EBITDA17.26
EV to Free Cash Flow-2.84
EV to Operating Cash Flow-15.59
Balance Sheet
Balaxi Pharmaceuticals Limited has ₹388.49M in cash and marketable securities with ₹565.23M in debt, giving a net cash position of -₹176.74M billion.
Cash & Marketable Securities₹388.49M
Total Debt₹565.23M
Net Cash-₹176.74M
Net Cash Per Share-₹3.20
Tangible Book Value Per Share₹39.71
Margins
Gross margin is 43.92%, with operating margin of 1.94%, and net profit margin of 0.52%.
Gross Margin43.92%
Operating Margin1.94%
Pretax Margin1.94%
Net Profit Margin0.52%
EBITDA Margin2.73%
EBIT Margin1.94%
Analyst Forecast
The average price target for Balaxi Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―